BPC-157 vs TB-500: Healing Peptide Research Comparison
BPC-157 vs TB-500: Healing Peptide Research Comparison
Research peptides for laboratory use only. Not approved by the FDA. Not for human consumption. By purchasing, you confirm you are a qualified researcher operating in a controlled laboratory setting.
Overview
BPC-157 and TB-500 are the two research peptides most commonly cited in tissue-repair literature. They are mechanistically distinct, derive from different biological origins, and act through different pathways, yet they appear together in research stacks frequently enough that the comparison question is one of the most common in vendor support inquiries. This guide walks through the mechanisms, the spec-sheet differences, the published research framing for solo vs combination use, and the SKUs Pure Chain Aminos offers in this category.
Mechanism Contrast
BPC-157
BPC-157, or Body Protection Compound 157, is a synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice. The native protein is a larger gastric peptide whose 15-residue stable fragment is the molecule of interest in published preclinical work. BPC-157 has been studied in tendon, ligament, muscle, gastrointestinal, and vascular contexts in animal models, with mechanistic emphasis on angiogenic activity, fibroblast proliferation, and growth factor receptor expression.
TB-500
TB-500 is a synthetic fragment of thymosin beta-4, a 43-amino-acid actin-sequestering protein expressed broadly across mammalian tissue. The TB-500 fragment is the active region most associated with the cell migration, angiogenesis, and tissue remodeling activity attributed to the parent molecule in published literature. The mechanistic emphasis is on actin regulation, endothelial cell migration, and wound-bed remodeling.
Pathway Differences
BPC-157 acts substantially through a growth-factor-receptor and angiogenesis axis, with documented preclinical effects on VEGFR2 expression and nitric oxide pathway interactions. TB-500 acts through actin sequestration and cell migration mechanics, with documented effects on endothelial migration and tissue cross-talk in wound models. The two pathways are not the same pathway, which is the underlying rationale for the combination protocols seen in research literature.
Side-by-Side Spec Comparison
| Spec | BPC-157 | TB-500 |
|---|---|---|
| Sequence length | 15 amino acids | 17-amino-acid active fragment of TB4 |
| Approximate molecular weight | ~1,419 Da | ~1,888 Da |
| Origin | Gastric peptide derivative | Thymosin beta-4 fragment |
| Primary research axis | Angiogenesis, growth factor | Actin regulation, migration |
| PCA vial sizes | 10mg, 15mg | 10mg |
| Combo SKU | BPC-157 / TB-500 10mg combo | |
Reconstitution Math
Reconstitution math is straightforward arithmetic against the vial mass and the bacteriostatic water volume used.
BPC-157 10mg: reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL, or 5,000 mcg/mL. A 0.1 mL draw (10 units on a U-100 syringe) is 500 mcg. With 1 mL of water, the concentration is 10 mg/mL.
BPC-157 15mg: reconstituted with 3 mL yields 5 mg/mL. With 1.5 mL, 10 mg/mL.
TB-500 10mg: reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL. A 0.1 mL draw is 500 mcg. With 1 mL, 10 mg/mL.
BPC-157 / TB-500 10mg combo (5mg of each per vial): reconstituted with 2 mL yields 2.5 mg/mL of each peptide, or 2,500 mcg/mL each. A 0.1 mL draw is 250 mcg of each.
These figures are arithmetic conversions of label mass to per-volume concentration for research compounding records. They are not protocol guidance.
When Researchers Stack vs Use Solo
The published literature framing for combination use rests on the orthogonal pathway argument. BPC-157 contributes angiogenic and growth-factor-receptor effects. TB-500 contributes actin-regulation and cell-migration effects. In wound-model literature, the combination is studied for the additive effect of two non-overlapping mechanisms acting on the same tissue process. Solo-use protocols are studied where the research question is specific to one pathway, or where dose-response data on a single agent is the goal.
For research operators, the combo SKU eliminates the compounding of two separate vials when both peptides are required at the same protocol concentration. The solo SKUs preserve flexibility for single-agent dose-response work or for protocols where the two agents are dosed at different concentrations.
PCA SKUs in This Category
Documentation Standard
Every BPC-157 and TB-500 lot shipped from Pure Chain Aminos carries a per-batch certificate of analysis with HPLC purity verification and mass spectrometry identity confirmation. Lot identifier on the COA matches the bottle. Method documentation is on the COA.
Get Started With WELCOME20
New researchers receive 20% off their first qualifying order with code WELCOME20 ($75 minimum). Browse BPC-157, TB-500, and the combo SKU, or browse the full Pure Chain Aminos catalog.
Research peptides for laboratory use only. Not approved by the FDA. Not for human consumption. By purchasing, you confirm you are a qualified researcher operating in a controlled laboratory setting.
Mechanism Comparison Table
The table below summarizes mechanism, half-life, and structural class differences referenced across published BPC-157 and TB-500 research literature. Researchers use this view to align experimental design with peptide pharmacokinetics.
| Attribute | BPC-157 | TB-500 (TB-4 fragment) |
|---|---|---|
| Source family | Pentadecapeptide derived from gastric protein BPC | Synthetic 17-residue fragment of full Thymosin Beta-4 |
| Approximate molecular mass | ~1419 Da | ~1810 Da |
| Receptor / pathway focus | Modulation of nitric oxide signaling, VEGFR-2, and growth-hormone-related pathways in animal models | Actin-binding (G-actin sequestration); upregulation of cell migration and angiogenesis markers |
| Reported half-life (animal model literature) | Short systemic half-life; investigators frequently cite stability advantages in gastric environments | Reported longer functional retention in tissue compartments after subcutaneous administration in rodent studies |
| Common research carrier | Bacteriostatic water reconstitution; refrigerated storage post-reconstitution | Bacteriostatic water reconstitution; refrigerated storage post-reconstitution |
Reconstitution Math Worked Example
Worked example for both peptides assuming a single 10mg lyophilized vial reconstituted with 2 mL of bacteriostatic water. Lab researchers should always verify against their own protocol and the COA-stated peptide content.
BPC-157 10mg vial + 2 mL bac water: 10 mg / 2 mL = 5 mg/mL = 5,000 mcg/mL. A 0.10 mL draw from an insulin syringe represents 500 mcg of reconstituted peptide. A 0.05 mL draw represents 250 mcg.
TB-500 10mg vial + 2 mL bac water: 10 mg / 2 mL = 5 mg/mL = 5,000 mcg/mL. The same volume math applies. A 0.20 mL draw represents 1,000 mcg (1 mg) of reconstituted peptide.
Researchers running the BPC-157 / TB-500 10mg combo SKU should account for both peptides in the same reconstitution and confirm both per-mL values against the COA. The Pure Chain Aminos bacteriostatic water reconstitution guide walks through volume selection step by step.
Stability and Storage Comparison
Both BPC-157 and TB-500 are shipped lyophilized in sealed glass vials. Lyophilized vials should be kept at 2-8 C, away from light, until reconstitution. After reconstitution with bacteriostatic water, both peptides are typically refrigerated and most laboratory protocols cited in the literature use the reconstituted vial within 14-30 days. TB-500 is generally reported as the more stable of the two in solution, though both benefit from cold-chain shipping and minimal freeze-thaw cycling. Researchers running long protocols should reconstitute smaller working aliquots rather than the full vial to limit thermal cycling.
Research Literature Snapshot
The selected references below are commonly cited in BPC-157 and TB-500 research planning. Citations are provided for literature awareness only and make no efficacy claim.
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157 — review of in vivo animal models. PubMed (multiple PMIDs in the Sikiric body of work).
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlighting to repair injured tissues. Trends in Molecular Medicine, 2005. PMID: 16002337.
- Crockford D et al. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences, 2010. PMID: 20536583.
- Chang CH et al. BPC-157 effects on tendon-derived cells in vitro. Journal of Applied Physiology, 2011. PMID: 21030672.
- Sosne G et al. Thymosin beta-4 and corneal wound studies. Annals of the New York Academy of Sciences, 2007. PMID: 17804813.
Researcher Considerations
BPC-157 is more frequently selected in research designs that focus on gastric mucosa, gut-barrier modeling, or tendon-cell models, given its derivation and the bulk of published in vivo literature. TB-500 is more frequently selected in research models focused on cardiac fibroblast migration, dermal wound, or systemic angiogenesis questions. Where a research design seeks to evaluate complementary actin-modulation plus VEGFR-pathway signaling in the same model, the combo SKU is sometimes used to keep a single reconstitution profile. Selection should follow the design hypothesis, the published model, and the reviewing committee’s protocol guidance — not popularity.
FAQ
Are BPC-157 and TB-500 the same class of peptide?
No. BPC-157 is a 15-residue pentadecapeptide derived from a stomach protein. TB-500 is a 17-residue synthetic fragment of full Thymosin Beta-4. They share research interest in tissue-recovery models but operate through distinct molecular pathways.
Why do COAs sometimes show purity above 99% for one and 98% for the other?
Purity is reported per HPLC method and varies by lot. Pure Chain Aminos posts the lot-specific COA so researchers can verify the actual purity of the vial they receive rather than relying on a marketing average.
How are BPC-157 and TB-500 typically stored before reconstitution?
Lyophilized vials are stored refrigerated at 2-8 C, sealed, away from light. After reconstitution with bacteriostatic water, vials are kept refrigerated and most cited research protocols use them within 14-30 days.
Can both peptides be reconstituted with the same bacteriostatic water?
Each peptide is reconstituted in its own vial. Researchers using the combo SKU follow the COA-stated peptide content for that vial.
Are these peptides FDA approved?
No. BPC-157 and TB-500 are not FDA approved. Both are sold strictly as research-grade reference compounds for laboratory use only.
Where can I review published research on these peptides?
Start with the Pure Chain Aminos BPC-157 research page and TB-500 research page, both of which link to PubMed citations.
Cross-Reference Reading
For more on lab vendor selection, see how to evaluate a research peptide vendor and the 2026 research peptide companies guide. For other comparisons, see Ipamorelin vs CJC-1295 and Tesamorelin vs Ipamorelin.
Compliance reminder: research peptides for laboratory use only. Not for human consumption. Citations support literature awareness, not efficacy claims.
